Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Marinus Pharmaceuticals Inc
MRNS | US
1.82
USD-0.03
-1.62%
MRNS | US
About Marinus Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
1.82
Open
1.85
High
1.96
Low
1.81
Marinus Pharmaceuticals Inc. a pharmaceutical company focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone) an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors a target for its anti-seizure antidepressant and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders such as PCDH19-related epilepsy and tuberous sclerosis complex. Marinus Pharmaceuticals Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co. Ltd. The company was incorporated in 2003 and is headquartered in Radnor Pennsylvania.
View LessMRNS | US
Risk
92.0
Sharpe
-0.73
Luna's Score
51/100
Recommendation
Hold
Luna says (MRNS | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
68.4%1 month
92.0%3 months
81.1%6 months
72.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
3.17
Debt to equity
-2.03
Debt to assets
1.10
Ent. to EBITDA
-34.47
Ent. to rev.
2.93
PEG
-
Other Fundamentals
EBITDA
-128.66M
MarketCap
100.25M
MarketCap(USD)
100.25M
Div. yield
-
Op. margin
-375.94
Erngs. growth
-
Rev. growth
32.50
Ret. on equity
-2.99K
Short ratio
4.95
Short perc.
5.87
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.32
Range1M
0.41
Range3M
0.92
Volumes: Market Activity
Rel. volume
0.63
Price X volume
841.58K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -34.47 | - | Cheaper |
| Ent. to Revenue | 2.93 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 3.17 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 81.10 | - | Par |
| Debt to Equity | -2.03 | -1.23 | Cheaper |
| Debt to Assets | 1.10 | 0.25 | Expensive |
| Market Cap | 100.25M | - | Emerging |
